‘Frame no-fault compensation policy for adverse events post COVID vaccination’

No-Fault Compensation Policy for Adverse Events Post COVID-19 Vaccination

UPSC Prelims + Mains Study Note

1. At a Glance

• The Supreme Court of India (March 2026) directed the Ministry of Health and Family Welfare (MoHFW) to frame a structured no-fault compensation policy for serious Adverse Events Following Immunisation (AEFI) arising from COVID-19 vaccination — a landmark public-health jurisprudence ruling. [S1]
• India currently has no uniform or structured policy mechanism to redress individuals who suffer serious adverse effects post-vaccination, despite running one of the world's largest immunisation drives. [S1]
• The concept is rooted in welfare-state liability: the State's duty of care to citizens who bear collective risk for public health — distinct from fault-based tort liability. [S1][S2]
• Directly relevant to GS-II (health governance, judiciary) and GS-IV (ethics of public health policy); high probability of Mains essay or application-based question in 2026–27 cycle.

2. Why in the News

• March 10–11, 2026: Supreme Court delivered judgment in Rachna Gangu v. Union of India (2026 INSC 218), directing the Centre to formulate a no-fault compensation framework for COVID-19 vaccine AEFIs. [S1][S2]
• The case arose from petitions seeking compensation for deaths and serious injuries allegedly caused by COVID-19 vaccines administered during India's national immunisation programme. [S1]
• The Bench of Justices Vikram Nath and Sandeep Mehta authored the judgment (Justice Nath writing). [S1][S4]
• The court also directed that AEFI-related data be placed in the public domain periodically — a transparency directive alongside the compensation mandate. [S1]

3. Background & Evolution

• Predecessors: India had causality-assessment committees (National and State AEFI Committees) but no accompanying statutory compensation mechanism. Assessment ≠ compensation.

4. Core Static Facts

Definitions - AEFI (WHO definition): Any untoward medical occurrence after vaccination that does not necessarily have a proven causal relationship with the vaccine. [S3] - No-Fault Compensation: Financial relief provided to a vaccine-injury victim without requiring proof of negligence by the manufacturer, administrator, or State. [S2][S3] - Serious AEFI: Events resulting in hospitalisation, permanent disability, or death.

Institutional Framework (existing) - National AEFI Committee: Constituted under MoHFW; conducts causality assessment of serious/severe AEFIs from the national immunisation programme. [S1] - State AEFI Committees: Conduct preliminary assessments before referral to national level. [S1] - Implementing Ministry: Ministry of Health and Family Welfare (MoHFW). [S1] - Nodal programme: Universal Immunisation Programme (UIP) under National Health Mission (NHM).

Case Citation - Rachna Gangu v. Union of India, 2026 INSC 218. [S2] - Bench: Justices Vikram Nath and Sandeep Mehta. [S1]

Global Benchmarks - As of 2010: Only 19 WHO Member States had vaccine injury compensation programmes; all were high-income nations. [S3] - COVAX No-Fault Compensation Programme: USD 150 million fund for 92 lower-middle-income countries for COVID-19 vaccine-related serious AEFIs. [S3]

COVID-19 Vaccines Used in India - Covishield (AstraZeneca/SII), Covaxin (Bharat Biotech), Sputnik V (Gamaleya/Dr. Reddy's).

5. Multi-Dimensional Analysis

Legal / Constitutional

• The SC held that the State–citizen relationship in a public vaccination programme cannot be viewed "through the prism of fault-based liability." [S1]
• The judgment does not constitute an admission of liability by the Union of India — a careful legal qualifier preventing retrospective flood of claims. [S1]
• Individuals retain the right to pursue other legal remedies (tort suits, consumer courts) alongside the no-fault framework. [S1]
• Gap in Article 21 (Right to Life) jurisprudence: mandatory/strongly nudged vaccination without a compensation safety net raises proportionality concerns.

Ethical / Governance

• Collective risk principle: Individuals vaccinated under State-driven programmes bear risks for societal benefit; ethical obligation of the State to share the burden of rare but severe adverse outcomes. [S2]
• No-fault schemes prevent chilling effects on vaccine uptake — fear of un-compensable harm drives hesitancy.
• Transparency gap: Absence of publicly accessible AEFI data undermines trust; SC directed periodic public disclosure. [S1]
• Risk of moral hazard: Over-broad no-fault schemes may disincentivise manufacturers from improving vaccine safety.

Social

• COVID-19 vaccination was described as an "unprecedented scale… collective societal necessity" — disproportionate burden fell on the poor and unaware. [S1]
• Families of AEFI victims (predominantly from lower-income strata without litigation capacity) benefit most from a no-fault, administrative (not court-based) redress mechanism.
• Gender dimension: Female caregivers and frontline health workers were early priority groups; their AEFI grievances need structured acknowledgement.

Administrative

• India's current structure performs causality assessment but stops short of compensation disbursement — an institutional design gap. [S1]
• A no-fault scheme requires defining: eligibility threshold (severity), quantum formula, time limit for filing, and adjudicating authority.
• Federal challenge: States run vaccination drives operationally under NHM; liability and fund-sharing between Centre and States must be structured.

Scientific / Technological

• Causality ≠ Compensation trigger: Under no-fault, a proven causal link is not required — claimant need only show temporal association + plausibility. [S3]
• The SC explicitly stated it had no intention to embark on a scientific inquiry into AEFI deaths — separating legal redress from epidemiological determination. [S1]
• AEFI data transparency (directed by court) supports post-market vaccine pharmacovigilance — feeds back into vaccine safety science.

Economic

• No-fault schemes reduce litigation costs for both claimants and the State compared to tort-based compensation.
• Risk of under-compensation if administrative awards are fixed at low levels vs. actual loss of earning/medical costs.
• Precedent for future epidemic/pandemic preparedness financing — could be linked to a dedicated Health Emergency Fund.

6. Recent Developments (Last 12–18 Months)

• March 10–11, 2026: Supreme Court judgment in Rachna Gangu v. Union of India (2026 INSC 218) — directed MoHFW to expeditiously frame no-fault compensation framework for COVID-19 vaccine AEFIs. [S1][S2]
• March 2026: SC directed AEFI-related data be placed in the public domain on a periodic basis — a transparency order. [S1]
• Government affidavit (filed before SC): Union of India provided data on total AEFI reported during the COVID-19 vaccination programme (exact figures not publicly disclosed in the article excerpt). [S4]
• SC clarified: formulation of the framework shall not be construed as admission of liability or fault by Union of India or any authority. [S1]

7. Prelims Hooks (High-Density Factual Bullets)

1. AEFI = "Adverse Event Following Immunisation" — defined by WHO as any untoward medical occurrence after vaccination that does not necessarily imply causal relationship with the vaccine. [S3]
2. The Supreme Court judgment in Rachna Gangu v. Union of India is cited as 2026 INSC 218. [S2]
3. The judgment was authored by Justice Vikram Nath (Bench: Justices Vikram Nath and Sandeep Mehta). [S1]
4. The Court directed the Ministry of Health and Family Welfare (not Ministry of Pharmaceuticals or NITI Aayog) to frame the policy. [S1]
5. As of 2010, only 19 WHO Member States had vaccine injury compensation programmes; all were high-income countries. [S3]
6. COVAX allocated USD 150 million for no-fault compensation in 92 lower-income countries for COVID-19 vaccine AEFIs. [S3]
7. Under a no-fault scheme, the claimant need not prove negligence — only that the adverse event followed immunisation and meets eligibility criteria. [S2][S3]
8. India's National AEFI Committee is constituted under MoHFW and does causality assessment — but currently has no compensation-disbursement mandate. [S1]
9. State AEFI Committees conduct preliminary assessments before referring cases to the National AEFI Committee. [S1]
10. SC ruled that the State-citizen relationship in public vaccination cannot be viewed through the prism of fault-based liability. [S1]
11. The SC's judgment does not preclude individuals from pursuing other available legal remedies (tort suits, consumer forums). [S1]
12. The three COVID-19 vaccines used in India's national drive: Covishield (SII/AstraZeneca), Covaxin (Bharat Biotech), Sputnik V (Gamaleya/Dr. Reddy's). [Knowledge]
13. The SC explicitly stated it had no intention to embark on a scientific inquiry into AEFI deaths — separating legal and epidemiological determinations. [S1]
14. Framing the no-fault policy shall not constitute an admission of liability by the Union of India. [S1]

8. Mains Relevance

GS Papers & Syllabus Headings

Plausible Mains Questions

1. "The Supreme Court's direction to frame a no-fault compensation policy for COVID-19 vaccine adverse events marks a shift from tort liability to welfare-state liability. Analyse the significance and challenges of such a framework for India." (GS-II, 15 marks)

2. "Discuss the ethical dimensions of a no-fault compensation scheme for vaccine injuries in the context of State-mandated immunisation programmes. How does it balance individual rights against collective public health imperatives?" (GS-IV, 10 marks)

3. "India's AEFI surveillance architecture identifies harm but provides no redress. Critically examine the institutional gaps and suggest a compensation framework design drawing on global models." (GS-II, 15 marks)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Wrong Ministry: Aspirants may confuse the implementing body. The directive is to Ministry of Health and Family Welfare — NOT Ministry of Pharmaceuticals, DBT, or NITI Aayog. [S1]

2. AEFI ≠ Vaccine Side Effect: AEFI is a WHO technical term denoting any adverse event temporally associated with vaccination — it does not imply proven causation. Conflating AEFI with confirmed vaccine harm is a factual error.

3. No-Fault ≠ Absolute Liability: No-fault removes the burden of proving negligence, but does not mean automatic compensation for every AEFI — eligibility criteria (severity thresholds, temporal windows) still apply. Do not confuse with "strict liability" under tort law.

4. Judgment ≠ Admission of Liability: The SC explicitly clarified the no-fault framework is not an admission of fault by the Government — aspirants who state "SC held vaccines caused deaths" misread the judgment. [S1]

5. National AEFI Committee ≠ Compensation Body: The National AEFI Committee performs causality assessment — it is a scientific/technical body, not a compensation authority. A separate adjudicating structure must be created by MoHFW as per the SC directive.

11. Sources

• [S1] SC asks Centre to frame 'no-fault compensation policy' for COVID-19 vaccine adverse effects — Onmanorama / The Hindu Bureau report, March 2026 — (Tier 4 / Article Excerpt)
• [S2] Explore No-Fault Compensation for COVID-19 vaccine effects, orders SC — SCC Times / SCC Online, March 11, 2026 — (Legal reporting; case citation confirmed)
• [S3] WHO — Injury Compensation (Vaccine Safety — GACVS) — who.int — (Tier 2)
• [S4] Rachna Gangu v. Union of India (2026 INSC 218) — case details — Verdictum / Supreme Court Observer — (Legal case repository)

Note: All facts traced to [S1]–[S4] above. Aspirants should track MoHFW's policy notification pursuant to the SC directive — that gazette/policy document will become the primary Tier 1 source once published.